Systematic reviews and clinical trials form the cornerstone of contemporary health research, providing robust, evidence‐based insights that guide clinical practice and policy. Systematic reviews ...

First High-Quality Study to Explore A Carnivore-Style Diet in Managing Metabolic Health, WhichAffects Millions of AmericansOver one-third of U.S. adults – or 115.2 million Americans – are prediabetic, ...

Utility of the 70-Gene MammaPrint Assay for Prediction of Benefit From Extended Letrozole Therapy in the NRG Oncology/NSABP B-42 Trial Patients with advanced lung cancer reporting at least moderate ...

An international, randomized, double-blind, placebo-controlled Phase III study—the largest of its kind for mpox—found that tecovirimat did not improve clinical outcomes for adults with clade II mpox ...

Remote clinical pharmacist impact on reducing total cost of care in Enhancing Oncology Model–enrolled oncology practices. Electronic patient-reported outcome-based weight management versus usual care ...

Thought LeadersAoife Hayes, Kevin O'Regan & Julie ScanlonClinical Trials Assitant, Operations Manager & Quality Assurance ManagerAtlantia Clinical Trials Food clinical trials may not be as familiar to ...

New vaccines are often evaluated in trials in which some participants receive a placebo. But not all studies can be designed this way. By Teddy Rosenbluth The Department of Health and Human Services ...

“Well, we don’t have as much evidence as we would like on steroid use during pregnancy,” the obstetrician warned my co-author, Natalia Emanuel, as she wrote a prescription for inhaled corticosteroids ...

The FDA’s dispute with biotech firm uniQure over Huntington’s gene therapy highlights growing tensions between innovation, ...

The antiviral drug tecovirimat (Tpoxx) is no better than placebo in achieving a shorter time to clinical resolution, reduced pain, or increased viral DNA clearance in adults infected with clade 2 mpox ...

Divergence in the post-progression interval suggests disparities may concentrate in subsequent-line therapy, surveillance, supportive care, or access to timely interventions outside trial ...